Report
Kelsey Tsai

PRA 1Q Results Track Expectations but Integration Plans Remain Foggy; Shares Fairly Valued

PRA Health’s first-quarter results put the company on track to meet our 2018 expectations. We are increasing our fair value estimate for the company to $81 per share from $80 to reflect the time value of money since our last model update. Given the cyclicality of the data solutions segment (legacy Symphony Health), we expect sales to accelerate toward the back half of the year, when data clients need to use up their annual budgets. Our full-year estimates remain near the mid-point of management’...
Underlying
PRA Health Sciences Inc.

PRA Health Sciences is a contract research organization engaged in providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. The company has two reportable segments: Clinical Research, which performs a range of services across the spectrum of clinical development programs, from the filing of investigational new drug applications and similar regulatory applications to conducting all phases of clinical trials; and Data Solutions, which provides data, analytics, technology, and consulting solutions to the life sciences market including market intelligence services, consulting and services, and apps and technology.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Kelsey Tsai

Other Reports on these Companies

PRAヘルスサイエンス、Synomaを使って臨床試験患者と実データを初めて連携

PRAヘルスサイエンス、Synomaを使って臨床試験患者と実データを初めて連携 製薬、バイオテクノロジーなどの治験依頼者は、臨床研究を時系列の実データに関連付けて医薬品開発を加速し、21世紀の治療法 (21st Century Cures Act) を順守可能に。 ノースカロライナ州ローリー発, May 14, 2021 (GLOBE NEWSWIRE) -- PRAヘルスサイエンス (PRA Health Sciences, Inc.) (NASDAQ: PRAH) は本日、PRA独自のテクノロジーであるSynoma®を使った革新的なトークン化ソリューションを発表した。これにより、医薬品開発のエビデンス生成を強化することができる。PRAのソリューションを使うと、最先端のプライバシーで臨床試験データと二次データセットを関連付けることができる。現在、大手製薬会社3社、および様々な規模の複数の製薬およびバイオテクノロジー企業が、Synomaを使って医薬品開発ポートフォリオ全体でデータをリンクし、分析を実施している。 PRAヘルスサイエンスの代表取締役副社長兼最高科学責任者のケント・テールケ (Kent Thoelke) は次のように述べている。「さまざまなソースからあらゆるタイプのデータを広く利用することができます。しかし、これまでは臨床試験データと実世界のデータから得...

Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch